Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma
Secondary Central Nervous System Lymphoma

Interventions

DRUG: Acalabrutinib

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]